Okay, let's tackle this question about the radioisotope used for treating bone cancer. First, I need to recall the common radioisotopes used in cancer treatment. Bone cancer treatments often involve radiation therapy, but specific isotopes might be used depending on the type of cancer and the approach.

The question is about which radioisotope is used. I remember that some isotopes are targeted at specific areas. For example, phosphorus-32 is used in some cancers, but maybe not bone. Radium-223 comes to mind because I've heard it's used for bone metastases, particularly in prostate cancer. Oh right, Radium-223 dichloride is a radiopharmaceutical that targets bone. It's an alpha emitter, which is effective for localized treatment with less damage to surrounding tissues.

Wait, other options could be like Strontium-89 or Samarium-153, which are also used for bone pain palliation. But the question is about treating the cancer itself, not just palliative care. Radium-223 is approved for use in patients with castration-resistant prostate cancer and bone metastases. It mimics calcium and is incorporated into the bone, delivering radiation to cancer cells in the bone.

So the correct answer is Radium-223. The other isotopes might be used for different purposes. For example, Iodine-131 is for thyroid cancer, and Phosphorus-32 for certain blood cancers. So each wrong option's incorrectness is because they're used elsewhere or for different types of cancer.

**Core Concept**
Bone cancer treatment often involves targeted radioisotopes that localize in bone tissue. **Radium-223 (Ra-223)** is a key isotope used for **bone-seeking** applications, particularly in **metastatic prostate cancer** with bone involvement. It acts as a calcium analog, targeting areas of active bone remodeling.

**Why the Correct Answer is Right**
**Radium-223** emits alpha particles, which have high linear energy transfer, effectively killing cancer cells in bone while sparing surrounding healthy tissue. It is FDA-approved for **castration-resistant prostate cancer** with symptomatic bone metastases. By mimicking calcium, Ra-223 is incorporated into bone, delivering localized radiation to tumor sites. Its short half-life (3.66 days) minimizes systemic toxicity.

**Why Each Wrong Option is Incorrect**
**Option A: Iodine-131** is used for thyroid cancer, not bone. **Option B: Phosphorus-32** targets blood cancers like polycythemia vera. **Option C: Strontium-89** provides palliative pain relief for bone metastases but is not a primary treatment. **Option D: Yttrium-90** is used in liver cancer and lymphoma, not bone.

**Clinical Pearl / High-Yield Fact**
Radium-223 is unique for its **alpha emission** and bone-targeting properties. Remember: **"Ra-223 = Rad bone cancer (prostate) + bone pain"**. Avoid confusing it with beta-emitters like Sr-89 or Sm-153, which are palliative.

**Correct Answer: D. Radium-223**

✓ Correct Answer: A. Sr